<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00233636</url>
  </required_header>
  <id_info>
    <org_study_id>1839IL/0070</org_study_id>
    <nct_id>NCT00233636</nct_id>
  </id_info>
  <brief_title>Iressa and Radiotherapy in the Treatment of the Locally Advanced Inoperable Squamous Cell Carcinoma of the Head and Neck</brief_title>
  <official_title>A 2 Part Phase 2 Trial to Evaluate ZD1839 (Iressaâ„¢) &amp; Radiotherapy in Patients w/Locally Advanced Inoperable Squamous Cell Carcinoma of the Head &amp; Neck</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <brief_summary>
    <textblock>
      The aim of the study is to determine if Iressa added to radiotherapy is effective and safe in
      shrinking tumour dimensions.
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <start_date>July 2003</start_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Tumour Response Rate, as complete response (CR) and partial response (PR) . Six months after Last Patient In.</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to progression, Overall survival, Duration of response. Six months after Last Patient In.</measure>
  </secondary_outcome>
  <enrollment>28</enrollment>
  <condition>Head and Neck Cancer</condition>
  <condition>Carcinoma, Squamous Cell</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Iressa (Gefitinib)</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Radiotherapy</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically Confirmed locally advanced Squamous Cell Carcinoma of Head and neck

          -  At least one measurable tumour lesion

        Exclusion Criteria:

          -  No previous treatment such as chemotherapy, radiotherapy and/or surgery for Carcinoma
             Head and Neck

          -  No other co-existing malignancies or malignancies diagnosed within the last 5 years
             with the exception of basal cell carcinoma or cervical cancer in situ

          -  Any evidence of severe or uncontrolled systemic disease (e.g. unstable or
             uncompensated respiratory, cardiac, hepatic or renal disease)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>AstraZeneca Italy Medical Director, MD</last_name>
    <role>Study Director</role>
    <affiliation>AstraZeneca</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Aviano</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Azienda</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Napoli</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Palermo</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ragusa</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>January 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 4, 2005</study_first_submitted>
  <study_first_submitted_qc>October 4, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 6, 2005</study_first_posted>
  <last_update_submitted>January 25, 2011</last_update_submitted>
  <last_update_submitted_qc>January 25, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 27, 2011</last_update_posted>
  <keyword>Squamous Cell Carcinoma of Head and Neck</keyword>
  <keyword>Inoperable locally advanced Squamous Cell Carcinoma of Head and Neck</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
    <mesh_term>Head and Neck Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gefitinib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

